---
title: "Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million"
description: "Armata Pharmaceuticals Inc. reported a third-quarter loss from operations of $7.8 million for the period ending September 30, 2025, an improvement from a $9.8 million loss in the same quarter of 2024."
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/265586472.md"
published_at: "2025-11-12T21:15:07.000Z"
---

# Armata Pharmaceuticals reports third quarter loss from operations of $7.8 million

> Armata Pharmaceuticals Inc. reported a third-quarter loss from operations of $7.8 million for the period ending September 30, 2025, an improvement from a $9.8 million loss in the same quarter of 2024. The company had $14.8 million in unrestricted cash as of September 30, 2025, up from $9.3 million at the end of 2024. Additionally, positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, were presented at IDWeek 2025.

Armata Pharmaceuticals Inc. reported a loss from operations of approximately $7.8 million for the third quarter ended September 30, 2025, compared to a loss of approximately $9.8 million for the same period in 2024. As of September 30, 2025, the company held around $14.8 million in unrestricted cash and cash equivalents, up from $9.3 million at the end of 2024. Approximately 36.3 million common shares were outstanding as of November 4, 2025. During the period, Armata highlighted positive results from the Phase 2a “diSArm” study of its lead therapeutic phage candidate, AP-SA02, for the treatment of complicated Staphylococcus aureus bacteremia, which were presented at IDWeek 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-110351), on November 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ARMP.US - Armata Pharmaceuticals](https://longbridge.com/en/quote/ARMP.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 在 FDA 积极审查后，Armata 将噬菌体疗法候选药物 AP-SA02 推进至第三阶段 | Armata Pharmaceuticals Inc. 已获得 FDA 批准，将其噬菌体疗法候选药物 AP-SA02 推进至第三阶段临床试验，此前其第二阶段 diSArm 研究取得了积极结果。该研究显示在治疗复杂的金黄色葡萄球菌菌血症方面的 | [Link](https://longbridge.com/en/news/272407601.md) |
| 由于美国 FDA 批准了后期感染试验，Armata Pharmaceuticals 股价大涨 | Armata Pharmaceuticals（ARMP.A）的股价在盘前交易中上涨了 24.8%，达到 8.26 美元，此次上涨是因为美国 FDA 批准了其针对复杂金黄色葡萄球菌菌血症的治疗 AP-SA02 的中期研究数据。即将进行的后期试 | [Link](https://longbridge.com/en/news/272411612.md) |
| 太空制药–商业航天的 “新场景” | 大摩表示，可复用火箭让发射成本暴降 10 倍，医药行业或将率先跑通商业闭环。微重力环境下药物晶体纯度更高、缺陷更少，胰岛素晶体体积可达地球 34 倍。行业先行者 Varda 已完成 HIV 药物太空结晶回收，目前融资 3.28 亿美元，目标 | [Link](https://longbridge.com/en/news/276549524.md) |
| Corcept 医疗｜8-K：2025 财年营收 7.61 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276787344.md) |
| Recursion Pharmaceuticals｜10-K：2025 财年营收 74.68 百万美元超过预期 |  | [Link](https://longbridge.com/en/news/276879117.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.